Skip to Content
Søg Menu

ASCO GI 2023 om colorektalcancer – I et dansk perspektiv

I denne MEDtalk giver Laurids Østergaard, overlæge på Onkologisk afdeling på Aalborg Universitetshospital, sit faglige perspektiv på udvalgte studier inden for colorektalcancer fra ASCO GI 2023.
Laurids Poulsen

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Wungki Park

First-Line Treatment of Claudin 18.2-Positive Metastatic Pancreatic Cancer with Zolbetuximab, Gemcitabine, and Nab-Paclitaxel

/ Wungki Park
ASCOGI23Pancreascancer Play the Video 4:43
Wungki Park

New potential standard-of-care for patients with CLDN18.2+/HER2- LA unresectable or mG/GEJ adenocarcinoma – an international perspective

/ Wungki Park
ASCOGI23HER2 Play the Video 3:18
Ken Kato

New option for 1. line treatment of advanced oesophagal squamous cell carcinoma – 29. Month Follow-up

/ Ken Kato
ASCOGI23Esofaguscancer Play the Video 11:05
Kohei Shitara

Promising Effect of Zolbetuximab and mFOLFOX6 Combination For Gastroesophageal Junction Adenocarcinoma

/ Kohei Shitara
ASCOGI23EsofaguscancerVentrikelcancer Play the Video 8:04
Stacey Cohen

No significant impact of plasma cfDNA levels on ctDNA detection rates across different MRD in patients with colorectal cancer

/ Stacey Cohen
ASCOGI23Colorektalcancer Play the Video 6:59
Laura Dawson

Positive effect of stereotactic body radiation therapy (SBRT) followed by sorafenib in patients with hepatocellular carcinoma

/ Laura Dawson
ASCOGI23Levercancer Play the Video 9:01
Josep Tabernero

New treatment option for refractory metastatic colorectal cancer – trifluridine/tipiracil plus bevacizumab

/ Josep Tabernero
ASCOGI23Colorektalcancer Play the Video 10:04

Late Breaking: Patients with Advanced Biliary Tract Cancer Can Safely be Treated with Antibiotics and Continue Treatment with ICI

/ BestPractice Nordic
ASCOGI23Galdegangscancer

Late Breaking: Zolbetuximab + Chemo as New Potential Standard Treatment for Patients with Unresectable, Metastatic Gastric, or Gastro-Esophageal Junction Adenocarcinoma

/ BestPractice Nordic
ASCOGI23EsofaguscancerGastrointestinal cancerVentrikelcancer
Back to top